Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of VEGFR2 activation by VEGF, neuropilin, and heparin.

Science advances·2026
Same author

Neuroinformed spectro-temporal-spatial attention with bi-hemispheric learning for EEG emotion recognition.

Biomedical physics & engineering express·2026
Same author

Development and validation of machine learning models for early diagnosis of hemophagocytic lymphohistiocytosis in pediatric Epstein-Barr virus infection.

BMC medical informatics and decision making·2026
Same author

MonoGID: geometry and illumination aware enhancement with distillation for self-supervised monocular endoscopic depth estimation.

BMC medical imaging·2026
Same author

Endobiliary Photodynamic Therapy in Cholangiocarcinoma: Clinical Outcomes, Patient Selection, and Procedural Context.

Current oncology (Toronto, Ont.)·2026
Same author

Macrophage-neutrophil crosstalk via the Selplg-Sell-YAP axis drives NETosis and MASH-associated liver fibrosis.

Hepatology (Baltimore, Md.)·2026

Related Experiment Video

Updated: Jun 4, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Recombinant Microcystis viridis lectin as a potential anticancer agent.

Yuqin Li1, Xuewu Zhang

  • 1College of Light Industry and Food Sciences, South China University of Technology, 381 Wushan Road, Guangzhou 510640, China.

Die Pharmazie
|February 3, 2011
PubMed
Summary

Recombinant Microcystis viridis lectin (R-MVL) shows promising anticancer effects against various cancer cell lines. This study highlights R-MVL

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jun 4, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Microcystis viridis lectin (MVL) is a glycoprotein from blue-green algae.
  • MVL has demonstrated significant anti-HIV activity.
  • The potential anticancer properties of MVL have not been extensively studied.

Purpose of the Study:

  • To investigate the in vitro anticancer activity of recombinant MVL (R-MVL).
  • To determine the efficacy of R-MVL against specific human cancer cell lines.

Main Methods:

  • Recombinant MVL (R-MVL) was synthesized and prepared.
  • The MTT assay was employed to assess cell viability and determine IC50 values.
  • Human cancer cell lines including HT-29, HepG2, SGC-7901, and SK-OV-3 were used.

Main Results:

  • R-MVL exhibited dose-dependent inhibition of cancer cell growth.
  • The IC50 values for R-MVL against HT-29, HepG2, SGC-7901, and SK-OV-3 were 40.20, 42.67, 49.87, and 53.40 microg/ml, respectively.
  • These findings indicate significant cytotoxic effects of R-MVL on tested cancer cell lines.

Conclusions:

  • This study provides the first evidence of R-MVL's potential anticancer activity.
  • R-MVL demonstrates promising therapeutic possibilities as an anti-cancer agent.
  • Further research into R-MVL's mechanism of action and in vivo efficacy is warranted.